Understanding Why Sulfonylureas Fail in Type 2 Diabetes
Author Information
Author(s): Maria Sara Remedi, Colin G. Nichols
Primary Institution: Washington University School of Medicine
Hypothesis
Chronic sulfonylurea treatment induces β-cell hyperexcitability leading to insulin secretory failure.
Conclusion
Chronic glibenclamide treatment causes loss of insulin secretory capacity due to β-cell hyperexcitability, but this failure is reversible after stopping the drug.
Supporting Evidence
- Chronic treatment with glibenclamide led to reduced insulin secretion in mice.
- Insulin secretory capacity was restored within hours after drug washout.
- Normal islet size and cell distribution were maintained despite treatment.
Takeaway
Mice treated with a diabetes drug called glibenclamide initially produce less insulin, but if the drug is stopped, they can start making insulin again.
Methodology
Mice were implanted with slow-release glibenclamide pellets to study the effects on insulin secretion over time.
Limitations
Findings from mice may not fully translate to humans.
Participant Demographics
Wild-type C57BL/6 male mice, 6 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website